Developing non-opioid pain drugs: Companies question if FDA is raising the bar
As the opioid epidemic rages on in the US, taking the lives of more than 100,000 people in the last year alone, companies developing new non-opioid pain drugs are questioning the FDA on its new draft guidance.
The draft in question, released in February, provides industry with some parameters around which it can work to develop these potentially less addictive pain meds. The guidance addresses FDA’s current thinking on 3 specific topics: development of non-opioid analgesics for acute pain, labeling claims and expedited programs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters